151 related articles for article (PubMed ID: 16178373)
1. Electron microscopic findings for micafungin-treated experimental pulmonary aspergillosis in mice.
Nakai T; Hatano K; Ikeda F; Shibuya K
Med Mycol; 2005 Aug; 43(5):439-45. PubMed ID: 16178373
[TBL] [Abstract][Full Text] [Related]
2. [Antifungal activity and clinical efficacy of micafungin sodium (Funguard)].
Ikeda F
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):339-44. PubMed ID: 14501170
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of micafungin for chronic pulmonary aspergillosis.
Izumikawa K; Ohtsu Y; Kawabata M; Takaya H; Miyamoto A; Sakamoto S; Kishi K; Tsuboi E; Homma S; Yoshimura K
Med Mycol; 2007 May; 45(3):273-8. PubMed ID: 17464848
[TBL] [Abstract][Full Text] [Related]
4. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
5. [Antifungal activity and clinical efficacy of micafungin (funguard)].
Ikeda F
Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):217-22. PubMed ID: 16282962
[TBL] [Abstract][Full Text] [Related]
6. Effective blood concentration of micafungin for pulmonary aspergillosis.
Shimoeda S; Ohta S; Kobayashi H; Yamato S; Sasaki M; Kawano K
Biol Pharm Bull; 2006 Sep; 29(9):1886-91. PubMed ID: 16946503
[TBL] [Abstract][Full Text] [Related]
7. Invasive pulmonary aspergillosis with hematological malignancy caused by Aspergillus terreus and in vitro susceptibility of A. terreus isolate to micafungin.
Tokimatsu I; Kushima H; Iwata A; Hashinaga K; Umeki K; Ohama M; Kohno K; Ishii H; Kishi K; Ogata M; Hiramatsu K; Saikawa T; Kadota J
Intern Med; 2007; 46(11):775-9. PubMed ID: 17541234
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis.
Clemons KV; Stevens DA
Med Mycol; 2006 Feb; 44(1):69-73. PubMed ID: 16805095
[TBL] [Abstract][Full Text] [Related]
9. Micafungin: pharmacology, experimental therapeutics and clinical applications.
Groll AH; Stergiopoulou T; Roilides E; Walsh TJ
Expert Opin Investig Drugs; 2005 Apr; 14(4):489-509. PubMed ID: 15882123
[TBL] [Abstract][Full Text] [Related]
10. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.
Okugawa S; Ota Y; Tatsuno K; Tsukada K; Kishino S; Koike K
Scand J Infect Dis; 2007; 39(4):344-6. PubMed ID: 17454899
[TBL] [Abstract][Full Text] [Related]
11. X-linked severe combined immunodeficiency (X-SCID) with high blood levels of immunoglobulins and Aspergillus pneumonia successfully treated with micafangin followed by unrelated cord blood stem cell transplantation.
Kobayashi S; Murayama S; Tatsuzawa O; Koinuma G; Kawasaki K; Kiyotani C; Kumagai M
Eur J Pediatr; 2007 Mar; 166(3):207-10. PubMed ID: 16915374
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.
Matsumoto S; Wakai Y; Nakai T; Hatano K; Ushitani T; Ikeda F; Tawara S; Goto T; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):619-21. PubMed ID: 10681328
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis.
Lewis RE; Albert ND; Kontoyiannis DP
J Antimicrob Chemother; 2008 May; 61(5):1140-4. PubMed ID: 18305201
[TBL] [Abstract][Full Text] [Related]
14. Micafungin: a therapeutic review.
Higashiyama Y; Kohno S
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment with micafungin (MCFG) of severe peritonitis due to Candida parapsilosis with chronic renal failure patient on hemodialysis].
Hashimoto H; Moriya R; Kamata K; Higashihara M; Yoshida K; Kume H
Kansenshogaku Zasshi; 2005 Mar; 79(3):195-200. PubMed ID: 15977561
[TBL] [Abstract][Full Text] [Related]
16. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
Petraitis V; Petraitiene R; Sarafandi AA; Kelaher AM; Lyman CA; Casler HE; Sein T; Groll AH; Bacher J; Avila NA; Walsh TJ
J Infect Dis; 2003 Jun; 187(12):1834-43. PubMed ID: 12792859
[TBL] [Abstract][Full Text] [Related]
18. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.
Dennis CG; Greco WR; Brun Y; Youn R; Slocum HK; Bernacki RJ; Lewis R; Wiederhold N; Holland SM; Petraitiene R; Walsh TJ; Segal BH
Antimicrob Agents Chemother; 2006 Feb; 50(2):422-7. PubMed ID: 16436692
[TBL] [Abstract][Full Text] [Related]
19. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
20. Micafungin.
Jarvis B; Figgitt DP; Scott LJ
Drugs; 2004; 64(9):969-82; discussion 983-4. PubMed ID: 15101786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
